Mylan Technologies Inc. Patent applications |
Patent application number | Title | Published |
20160136107 | STORAGE STABLE TRANSDERMAL PATCH OF ROTIGOTINE - Disclosed is a transdermal delivery device comprising a backing layer, a release liner, and an adhesive layer between the backing layer and the release liner, the adhesive layer comprising an active agent solubilized in an adhesive matrix, the adhesive matrix comprising a mixture of biocompatible polymers, wherein the active agent is soluble in at least one of the biocompatible polymers. | 05-19-2016 |
20150246006 | TRANSDERMAL SYSTEMS HAVING CONTROL DELIVERY SYSTEM - Transdermal delivery systems are disclosed including a backing layer, a polymer membrane within the backing layer, an adhesive layer for attaching the delivery system to the patient's skin or mucosa, and a releasable layer covering the adhesive layer prior to use, the polymer membrane impregnated with sufficient fluid medium to alter the rate of transmission of an active agent through the polymer membrane, with the amount of fluid medium being greater than the amount retained by the fluid membrane upon drying. | 09-03-2015 |
20140249492 | TRANSDERMAL PATCH INCORPORATING ACTIVE AGENT MIGRATION BARRIER LAYER - Devices for administration of one or more active agents to the skin or mucosa of a host are formed in the nature of a double-disk patch. One outer layer functions as the primary adhesive layer for adhering the patch to the host. The other inner layer contains at least one active agent to be administered to the host. The inner layer is bonded to the outer layer through an opening provided in an interposed active agent impermeable release layer. The release layer separates a circumferential portion of the active agent containing inner layer from the outer adhesive layer to inhibit migration of the active agent therebetween. | 09-04-2014 |
20140243379 | ADHESIVE MIXTURE FOR TRANSDERMAL DELIVERY OF HIGHLY PLASTICIZING DRUGS - Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs. | 08-28-2014 |
20130018078 | ADHESIVE MIXTURE FOR TRANSDERMAL DELIVERY OF HIGHLY PLASTICIZING DRUGS - Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs. | 01-17-2013 |
20110151003 | TRANSDERMAL SYSTEMS CONTAINING MULTILAYER ADHESIVE MATRICES TO MODIFY DRUG DELIVERY - A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. | 06-23-2011 |
20110123613 | EXTENDED-RELEASE DOSAGE FORM - Provided are pharmaceutical formulations comprising sustained release particles each having an inner core bead comprising an active pharmaceutical ingredient an intermediate coating substantially surrounding the inner core bead, and an outer coating substantially surrounding the intermediate coating comprising a pH independent polymer. Also provided is a pharmaceutical formulation comprising two bead populations wherein each of the first and second bead populations have a different drug release profile. Also provided is a method of preparing an extended release dosage composition comprising one or more bead populations. | 05-26-2011 |
20110106022 | LONG-WEARING REMOVABLE PRESSURE SENSITIVE ADHESIVE - A medical grade adhesive comprises a mixture of at least one cross-linkable pressure sensitive adhesive component and at least one non-cross-linkable pressure-sensitive adhesive component, wherein the amount of each of said components is such that the resultant adhesive can adhere to human skin for a period of up to about 7-10 days but can be removed without causing trauma to the skin. | 05-05-2011 |
20100086582 | AMORPHOUS ROTIGOTINE TRANSDERMAL SYSTEM - The present invention refers to a transdermal delivery device comprising a backing layer, an adhesive matrix layer comprising a supersaturated concentration of rotigotine substantially in amorphous form within the adhesive matrix, and a release liner. The present invention also refers to a method of preparing an adhesive matrix containing a supersaturated amount of rotigotine substantially in amorphous form. Further, the present invention refers to a method of stabilizing and a method of reestablishing the meta-stable amorphous-drug transdermal system during its manufacturing, storing, shipping and handling process. | 04-08-2010 |
20090299304 | STABILIZED TRANSDERMAL DRUG DELIVERY SYSTEM - A solid dispersion transdermal drug delivery system comprising a therapeutic agent in a stable amorphous form and a combination polymeric stabilizing and dispersing agent having a hydrogen bond-forming functional group, and a method of manufacturing these systems is provided. The weight ratio of the combination polymeric stabilizing and dispersing agent to the therapeutic agent is also disclosed. | 12-03-2009 |
20090234308 | Transdermal systems having control delivery system - Transdermal delivery systems are disclosed including a backing layer, a polymer membrane within the backing layer, an adhesive layer for attaching the delivery system to the patient's skin or mucosa, and a releasable layer covering the adhesive layer prior to use, the polymer membrane impregnated with sufficient fluid medium to alter the rate of transmission of an active agent through the polymer membrane, with the amount of fluid medium being greater than the amount retained by the fluid membrane upon drying. | 09-17-2009 |
20080305155 | Transdermal Systems Containing Multilayer Adhesive Matrices to Modify Drug Delivery - A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. | 12-11-2008 |
20080226698 | Amorphous drug transdermal systems, manufacturing methods, and stabilization - The present invention refers to a transdermal delivery device comprising a backing layer, an adhesive matrix layer comprising a supersaturated concentration of an active agent substantially in amorphous form within the adhesive matrix, and a release liner. The present invention also refers to a method of preparing an adhesive matrix containing at least one supersaturated active agent substantially in amorphous form. Further, the present invention refers to a method to stabilize and a method to reestablish the meta-stable amorphous-drug transdermal system during its manufacturing, storing, shipping and handling process. | 09-18-2008 |